BFEC
FLXN

Benjamin F. Edwards & Company’s Flexion Therapeutics, Inc. FLXN Stock Holding History

Benjamin F. Edwards & Company’s Portfolio FLXN Stock Details FLXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-100
Closed -$1K – 2012
2019
Q2 		$1K Sell
100
-200
-67% -$2.31K ﹤0.01% 1888
2019
Q1 		$4K Hold
300
– – ﹤0.01% 1550
2018
Q4 		$3K Buy
+300
New +$4.7K ﹤0.01% 1578

Other funds holding FLXN

MVP
Miller Value Partners Sarasota, Florida $423M AUM 49.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return

Benjamin F. Edwards & Company's FLXN Position: Q3 2019 in Review

Benjamin F. Edwards & Company sold out of Flexion Therapeutics, Inc. (FLXN) in Q3 2019, closing a stake of 100 shares — an estimated $1K sold.

Benjamin F. Edwards & Company first reported a position in FLXN in Q4 2018 and held it in 3 quarters. The position peaked at $4K in Q1 2019. 126 funds tracked by Wall St. Rank hold FLXN as of Q3 2019.

  • Benjamin F. Edwards & Company reported no remaining Flexion Therapeutics, Inc. position as of Q3 2019 after selling out during the quarter.
  • Benjamin F. Edwards & Company sold 100 Flexion Therapeutics, Inc. shares in Q3 2019, an estimated $1K.
  • Benjamin F. Edwards & Company first reported a position in Flexion Therapeutics, Inc. in Q4 2018 and held it in 3 quarters.
  • Benjamin F. Edwards & Company's Flexion Therapeutics, Inc. position peaked at $4K in Q1 2019.
  • 126 funds tracked by Wall St. Rank held Flexion Therapeutics, Inc. as of Q3 2019.

Based on Benjamin F. Edwards & Company's 13F filing for Q3 2019, filed 5 Nov 2019.